Connective Tissue Disease Market Size Is Anticipated to Grow at a USD 11.5 Billion By 2022

Research Reports

Jan 22, 2021

Connective tissue diseases can occur due to genetic malformation or as a side-effect of autoimmune diseases. Mixed connective tissue disease (MCTD) is a rare autoimmune disease which shares symptoms of lupus, scleroderma, and multiple sclerosis. The high chances of the disease within females than males can elicit the demand for cures for the disease and drive the market demand.

Connective tissue diseases are a group of maladies which can affect cellular structures that connect various organs of the human body. This disease is characterized by inflamed tissues or various protein molecules have become injured by inflammation. The global connective tissue disease market report by Market Research Future (MRFR) outlines in detail the various segments as well as getting a perspective on major regions with respect to the market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/4977

The global connective tissue disease market is predicted to exhibit 11.5% CAGR from 2017 to 2023 (forecast period). Connective tissue diseases affect more than 200 tissues in the human body. According to the Pan African Medical Journal, in 2017, mixed connective tissue diseases were found to be recurring among Asians. Changes in genes due to changes in climatic conditions, pollution levels, and other external factors can drive the market demand.

Segmentation Analysis

The global connective tissue disease market is segmented by diagnosis, treatment, and end-user.

By diagnosis, it is segmented into anti-nuclear antibody test (ANA), X-ray examination, physical examination, and others.

By treatment, it is segmented into cytotoxic drugs, antimalarial drugs, cortisone drugs/steroids, non-steroidal anti-inflammatory drugs (NSAIDs), and others. Cortisone drugs/steroids are assumed to gain the highest demand during the forecast period. The upsurge of the segment can be attributed to the efficacy of these drugs in alleviating the pain associated with inflamed tissues.

By end-user, it is segmented into hospitals, diagnostic clinics, and others.

Competitive Analysis

Major industry participants in the global connective tissue disease market include Pfizer, Abbott Laboratories, AstraZeneca, Amgen Inc., F. Hoffmann-La Roche Ltd, Biogen, AutoImmune Inc., Bayer AG, LUPIN, Eli Lilly and Company, Johnson & Johnson, and others. Research and development is the primary focus of these players to increase their market share and create a niche. Boehringer Ingelheim announced the approval of its drug, Ofev, by the Food and Drug Administration (FDA) for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).

Regional Analysis

The Middle East & Africa, the Americas, Asia Pacific (APAC), and Europe are regions taken into consideration in the compilation of the global connective tissue disease market report.

The Americas held the largest market share and touted to dominate the global market due to rising awareness of the disease among the populace and large healthcare expenditure by governments of Canada and the U.S. Emergence of tissue dissociation for development of monoclonal antibodies and manufacture of effective drugs for combating autoimmune disorders. Rising focus on research and development by pharmaceutical and healthcare sectors can fetch significant revenue for the market. Clinical trials are being conducted by pharma companies to test the efficacy of drugs. This is exemplified with Corbus Pharmaceuticals calling for willing participants for its latest drug, Lenabasum, for treating systemic sclerosis.

Europe is expected to be the second biggest region in the market due to insurance coverage policies and new reimbursement schemes between insurance companies and drug manufacturers. Support for research and development by governments in the European Union for treatment of autoimmune diseases and tissue disorders can bring relief to patients as well as brand new growth opportunities to the global connective tissue disease market.

The APAC region is expected to exhibit a robust growth rate due to the large healthcare expenditure, developing technology, and large patient pool. According to the Australian Institute of Health and Welfare, the total healthcare expenditure had risen sharply due to prevalence of various chronic diseases.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/connective-tissue-disease-market-4977

Browse More Reports at:

Population Health Management Market Size, Share, Growth, Industry Trends Analysis, Forecast 2023

Cosmetic Surgery Market Size, Growth and Share Analysis, 2023

Infusion Pump Market Size Analysis, Share | Application, 2023

Healthcare Revenue Cycle Management Market Growth, Size, Share Forecast to 2027 | MRFR

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Tags: Connective Tissue Disease Market Share, Connective Tissue Disease Market Trends, Connective Tissue Disease Market Size, Connective Tissue Disease Market Growth, Connective Tissue Disease Industry, Connective Tissue Disease Market Insights, Connective Tissue Disease Market Dynamics, Connective Tissue Disease Market Key Players See Campaign: https://www.marketresearchfuture.com/reports/connective-tissue-disease-market-4977
Contact Information:
Akash Anand Market Research Future +1 646 845 9312 Email: [email protected]